奥美医疗(002950) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥758,656,819.43, representing a 1.64% increase compared to ¥746,413,148.74 in the same period last year[5]. - Net profit attributable to shareholders decreased by 7.86% to ¥86,502,742.68 from ¥93,879,127.79 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥74,064,711.29, down 11.39% from ¥83,581,007.83 in the previous year[5]. - Basic and diluted earnings per share were both ¥0.1366, down 7.83% from ¥0.1482 year-on-year[5]. - The net profit for the current period is 86,652,875.66, a decrease of 7.8% compared to 94,126,734.14 in the previous period[15]. - Operating profit for the current period is 112,646,587.37, down from 115,891,801.50, reflecting a decline of 2.0%[15]. - Total comprehensive income for the current period is 87,303,886.56, compared to 91,049,459.30 in the previous period, reflecting a decrease of 4.0%[15]. - Basic earnings per share for the current period is 0.1366, down from 0.1482 in the previous period, a decline of 10.7%[16]. Assets and Liabilities - The company's total assets increased by 3.33% to ¥5,227,172,701.54 from ¥5,058,919,305.88 at the end of the previous year[5]. - Total assets increased to ¥5,227,172,701.54 from ¥5,058,919,305.88, showing a growth of approximately 3.34%[12]. - Total liabilities rose to ¥1,700,968,927.86 from ¥1,610,882,574.54, indicating an increase of about 5.58%[12]. Cash Flow - The net cash flow from operating activities was ¥187,391,041.57, a slight decrease of 0.21% compared to ¥187,779,958.15 in the same period last year[5]. - Cash flow from operating activities is 187,391,041.57, slightly down from 187,779,958.15, indicating a stable cash generation[16]. - Cash flow from investing activities shows a net inflow of 49,688,746.84, a significant improvement from a net outflow of -39,159,163.55 in the previous period[17]. - Cash flow from financing activities has a net inflow of 63,487,473.60, recovering from a net outflow of -82,168,677.63 in the previous period[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 39,155[9]. - Major shareholders include Cui Jinhai with 23.02% and Cheng Hong with 15.14% of the shares[9]. Operational Efficiency - The company's net profit margin improved, with net income figures reflecting operational efficiency despite rising costs[14]. - Total operating revenue for the current period reached ¥758,656,819.43, an increase from ¥746,413,148.74 in the previous period, reflecting a growth of approximately 1.67%[14]. - Total operating costs amounted to ¥659,488,618.50, up from ¥644,083,767.68, indicating an increase of about 2.08%[14]. - Research and development expenses rose to ¥29,820,611.27, compared to ¥18,459,891.44 in the previous period, marking a significant increase of approximately 61.5%[14]. Future Plans - The company plans to expand its market presence and invest in new technologies to drive future growth[14].